Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience-Reference-Cited by-同舟云学术

Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience

Published:2018-09 Issue:3 Volume:17 Page:e451-e456
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Zhang Hanbo,Kellett Curtis,Lambert Pascal,Kim Christina A.

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference31 articles.

1. Pancreatic cancer;Hidalgo;N Engl J Med,2010

2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

3. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study;Colucci;J Clin Oncol,2010

4. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer;Abou-Alfa;J Clin Oncol,2006

5. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer;Heinemann;J Clin Oncol,2006

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab‐paclitaxel plus gemcitabine as second or later‐line treatment;Cancer Medicine;2024-06

2. The prognostic impact of surufatinib for the treatment of advanced pancreatic ductal adenocarcinoma: A single center retrospective study;2024-05-21

3. Systemic therapy for metastatic pancreatic cancer;Malignant tumours;2023-10-09

4. Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data;Pancreas;2023-04

5. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer;Cancers;2023-01-05